TG Therapeutics, Inc.

NASDAQ:TGTX

Biotechnology

Healthcare
$66.12 +2.00%

+$1.03 today

Market cap
$9.99B
Beta
1.68
P/E (TTM)
16.4
EPS (TTM)
$3.20
52W Low $25.28High $53.98

Volume 1.87M

Average 2.15M

TGTX Other Financing Activities

Financing cash flows not reported separately.

TG Therapeutics, Inc.NASDAQ: TGTX

Other Financing Activities · Q3 FY2026 · quarter ended Sep 2026

Other financing activities outflow grows to $0

Q3 FY2026 other financing activities was $0, compared with $0 a year earlier. Trailing-twelve-month other financing activities was $0.

Context

  • Other financing activities amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Other financing activities increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other financing activities holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$0— QoQ
Last fiscal yearDec 2025
$0-100.0% YoY
LTMSep 2026
$0-100.0% YoY
Other Financing Activities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Financing Activities history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
-100.0%

Other Financing Activities vs competitors

How TGTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so other financing activities is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -100.0% is the 3rd highest of 5, against a peer median of -53.6%.
  • Other financing activities amounts to 0.0% of revenue for TGTX, versus a peer median of 88.6%.
TGTX Competitors
Other Financing Activities for TGTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GMABGenmab A/SLTM Jun 2026$5.21B USD——126.1%
MGNXMacroGenics, Inc.LTM Mar 2026$139.12M USD+52398.9%+394.4%88.6%
ADCTADC Therapeutics S.A.LTM Mar 2026$92.24M USD-7.2%—116.5%
ADAGAdagene Inc.LTM Jun 2024$2.15M USD——264.1%
TGTXTG Therapeutics, Inc.LTM Sep 2026$0 USD-100.0%—0.0%
XNCRXencor, Inc.LTM Jun 2026$0 USD-100.0%—0.0%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$0 USD——0.0%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$0 USD———
IPHAInnate Pharma S.A.FY2025€0 EUR-100.0%—0.0%
Peer median (excluding TGTX) —-53.6%+394.4%88.6%

Competitors are the stored peer set for TGTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(348.1M)(198.34M)12.67M23.38M447.18M
Depreciation & Amortization494K515K423K280K244K
Deferred Income Tax517K000(348M)
Stock-Based Compensation61.27M19.19M37.93M42.54M64.67M
Change in Working Capital(12.22M)(1.65M)(84.66M)(109.3M)(194.54M)
Accounts Receivables(1.39M)1.39M(51.09M)(78.09M)(176.44M)
Inventory(15.99M)0(36.94M)(66.85M)(33.45M)
Accounts Payables15.99M(11.01M)192K055.88M
Other Working Capital(10.83M)7.97M3.18M35.65M(40.52M)
Other Non-Cash Items2.4M4.11M2.22M2.58M5.67M
Operating Cash Flow(295.63M)(176.17M)(31.41M)(40.52M)(24.77M)
Capital Expenditures(401K)(14K)0(45K)(214K)
Acquisitions (Net)(69K)20M000
Purchases of Investments(55.53M)(107.27M)(146.88M)(311.89M)(223.49M)
Sales of Investments55.6M87.28M96.23M310.9M237.5M
Other Investing Activities69K(20M)000
Investing Cash Flow(332K)(20.01M)(50.65M)(1.04M)13.8M
Debt Repayment40M(975K)25M137.26M0
Common Stock Issued2.22M584K46.3M01.51M
Common Stock Repurchased000(8.76M)(91.24M)
Dividends Paid00000
Other Financing Activities(800K)01.41M25K0
Financing Cash Flow41.42M(391K)72.71M128.53M(89.73M)
Effect of Forex Changes00000
Net Change in Cash(254.55M)(196.57M)(9.36M)86.97M(100.7M)
Free Cash Flow(296.04M)(176.18M)(31.41M)(40.56M)(24.99M)

TG Therapeutics, Inc.

NASDAQ:TGTX

Intrinsic Alpha fair value

Locked

Current Price

$66.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.